A Phase 2 interventional study of Adalimumab (40 mg sc every other week) and Placebo in Erosive Osteo-Arthritis, sponsored by University Hospital, Ghent. Completed at 1 site in Belgium. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2009-02-09.
Sponsored by University Hospital, Ghent · Phase 2, Interventional, and Treatment
Patients will be randomized into two groups (1/1) during one year:
The effect on x-rays and clinical parameters will be evaluated.
4,398 studies on the registry are indexed under Osteoarthritis; 582 are open to participants now.
This study's enrollment of 60 is below the median of 70 across 3,440 interventional studies indexed under Osteoarthritis.
Browse Osteoarthritis studies →University Hospital, Ghent is the lead sponsor of 665 studies on the registry; 156 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 4 (80%) have results posted.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria:
Drug - adalimimab sc
Drug: Adalimumab (40 mg sc every other week)
Placebo
Drug: Placebo
Adalimumab (40 mg sc every other week)
Placebo
Evaluation of x-rays
Evaluation of clinical parameters (pain, daily functioning, etc.)
This study is completed, as verified in Feb 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Ghent